IRCT201301148430N7 IRCT 2014-02-25 Neuroscience Research center Effect of pentoxifylline on multiple sclerosis treatment Investigating the effects of Pentoxifylline on reduction of relapse frequency in patients with relapsing-remitting multiple sclerosis (RRMS) 2012-06-30 anticipated 44 Complete https://irct.ir/trial/8893 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A MULTIPLE SCLEROSIS. Intervention 1: intervention group : tablet Pentoxifylline 800 mg daily for 2 months. Intervention 2: control group: placebo with similar dose of intervention group.

public akbar hamzei moghaddam MD

shafa hospital

kerman Iran (Islamic Republic of) 7618751151 +98 34121157809 shafahospital@kmu.ac.ir kerman university of medical science scientific rostam seifaddini MD

shafa hospital

kerman Iran (Islamic Republic of) 7618751151 +98 34121157809 shafahospital@kmu.ac.ir kerman university of medical science Iran (Islamic Republic of) inclusion criteria: new case of MS compatible with MC donalds ؛relapsing -remitting pattern ؛ age between 20-40 Y/O exclusion criteria: other patterns of MS except RRMS؛ other immunomodulatory medications use except beta interferon؛pregnancy and lactation ؛concurrent autoimmune diseases and it's related drugs؛allergy to drug ؛liver disease؛renal disease ؛antihypertensive and ASA and anticoagolant drugs 20 years 40 years Both G35 Multiple sclerosis Treatment - Drugs Treatment - Drugs intervention group : tablet Pentoxifylline 800 mg daily for 2 months control group: placebo with similar dose of intervention group Recurrence. Timepoint: monthly. Method of measurement: clinical examination. Expanded Disability Status Scale. Timepoint: before of the treatment, 6 months after and at the end of the treatment. Method of measurement: clinical examination. Neuroscience Research center Approved 2012-07-01 RESEARCH AND TECHNOLOGY KERMAN UNIVERSITY OF MEDICAL SCIENCE KERMAN,FOURWAY TAHMASABAD KERMAN Iran (Islamic Republic of)